A stem cell epigenome is associated with primary nonresponse to CD19 CAR T cells in pediatric acute lymphoblastic leukemia

CD19 chimeric antigen receptor T-cell therapy (CD19-CAR) has changed the treatment landscape and outcomes for patients with pre–B-cell acute lymphoblastic leukemia (B-ALL). Unfortunately, primary nonresponse (PNR), sustained CD19(+) disease, and concurrent expansion of CD19-CAR occur in 20% of the p...

Descripción completa

Detalles Bibliográficos
Autores principales: Masih, Katherine E., Gardner, Rebecca A., Chou, Hsien-Chao, Abdelmaksoud, Abdalla, Song, Young K., Mariani, Luca, Gangalapudi, Vineela, Gryder, Berkley E., Wilson, Ashley L., Adebola, Serifat O., Stanton, Benjamin Z., Wang, Chaoyu, Milewski, David, Kim, Yong Yean, Tian, Meijie, Cheuk, Adam Tai-Chi, Wen, Xinyu, Zhang, Yue, Altan-Bonnet, Grégoire, Kelly, Michael C., Wei, Jun S., Bulyk, Martha L., Jensen, Michael C., Orentas, Rimas J., Khan, Javed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2023
Materias:
Lymphoid Neoplasia
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10440404/
https://www.ncbi.nlm.nih.gov/pubmed/36607839
http://dx.doi.org/10.1182/bloodadvances.2022008977

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10440404/
https://www.ncbi.nlm.nih.gov/pubmed/36607839
http://dx.doi.org/10.1182/bloodadvances.2022008977

Ejemplares similares